Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of the study is to evaluate the safety, tolerability, PK and PD of a single-dose of ALXN1007 in healthy volunteers.

Key facts

Study ID

NCT01454986

Run by

Alexion Pharmaceuticals, Inc.

People needed

64

Starts

2011-11-01

Expected to finish

2013-10-01

Last updated by the study team

2017-02-03

Who can join

Age: 25 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy individuals 25 to 55 years of age with documented vaccination with MCV4.

You may not qualify if…

• Abnormal renal or liver function.
• History of meningococcal disease.
• History of Guillain-Barre syndrome.
• Known infection with HIV or Hepatitis B or C.

Where it is running

• PAREXEL Baltimore EPCU — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.